Shionogi's stroke drug fails mid-stage; Bayer's Hyrnuo gets expanded label

Plus news about Tevard Biosciences, Disc Medicine, InduPro, EMD Serono and Frazier Life Sciences. Shionogi fails mid-stage stroke trial: The company’s experimental drug redasemtide didn’t meet the primary endpoint in a ...